Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AbbVie : New Findings Reported from AbbVie Describe Advances in Biochemistry [Identification of novel resistance mechanisms to NAMPT inhibition via the de...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:11pm CET

New Findings Reported from AbbVie Describe Advances in Biochemistry [Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation]

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Chemistry - Biochemistry. According to news reporting out of North Chicago, Illinois, by NewsRx editors, research stated, "Cancer cells have an unusually high requirement for the central and intermediary metabolite nicotinamide adenine dinucleotide (NAD(+)), and NAD(+) depletion ultimately results in cell death. The rate limiting step within the NAD(+) salvage pathway required for converting nicotinamide to NAD(+) is catalyzed by nicotinamide phosphoribosyltransferase (NAMPT)."

Our news journalists obtained a quote from the research from AbbVie, "Targeting NAMPT has been investigated as an anti-cancer strategy, and several highly selective small molecule inhibitors have been found to potently inhibit NAMPT in cancer cells, resulting in NAD(+) depletion and cytotoxicity. To identify mechanisms that could cause resistance to NAMPT inhibitor treatment, we generated a human fibrosarcoma cell line refractory to the highly potent and selective NAMPT small molecule inhibitor, GMX1778. We uncovered novel and unexpected mechanisms of resistance including significantly increased expression of quinolinate phosphoribosyl transferase (QPRT), a key enzyme in the de novo NAD(+) synthesis pathway. Additionally, exome sequencing of the NAMPT gene in the resistant cells identified a single heterozygous point mutation that was not present in the parental cell line. The combination of upregulation of the NAD(+) de novo synthesis pathway through QPRT over-expression and NAMPT mutation confers resistance to GMX1778, but the cells are only partially resistant to next-generation NAMPT inhibitors."

According to the news editors, the research concluded: "The resistance mechanisms uncovered herein provide a potential avenue to continue exploration of next generation NAMPT inhibitors to treat neoplasms in the clinic."

For more information on this research see: Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation. Biochemical and Biophysical Research Communications, 2017;491(3):681-686. Biochemical and Biophysical Research Communications can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Biochemical and Biophysical Research Communications - www.journals.elsevier.com/biochemical-and-biophysical-research-communications/)

Our news journalists report that additional information may be obtained by contacting T.H. Huang, AbbVie Inc, North Chicago, IL 60064, United States. Additional authors for this research include L.T. Lam, K.L. Longenecker, M.H. Bui, K.B. Idler, K.B. Glaser, J.L. Wilsbacher, C. Tse, W.N. Pappano and J. Guo (see also Chemistry - Biochemistry).

Keywords for this news article include: North Chicago, Illinois, United States, North and Central America, Biochemistry, Chemistry, Oncology, Genetics, Cancer, AbbVie.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
12/15 ABBVIE : A new role for Bcl-XL in fibrosis
12/15 Wall Street falls as investors fret about tax bill passage
12/14 ABBVIE : Recent Data from A.J. Epstein and Co-Authors Highlight Findings in Endo..
12/14 ABBVIE : New Molecular Pharmaceutics Findings from AbbVie Discussed (Impact of P..
12/14 ABBVIE : IMBRUVICA Data Provide Insights Into Its Potential Treatment Benefits
12/14 ABBVIE : Announces Phase 3 Study of VENCLEXTA VENCLYXTO in Combination with Ritu..
12/13 ABBVIE : Roche boast stellar PhIII leukemia data for a breakthrough combo with b..
12/12 ABBVIE : IMBRUVICA Pooled Analysis Suggests Benefit in Progression-Free Survival..
12/12 ABBVIE : IMBRUVICA Patient-Reported Outcomes Data Detail Long-Term Improvement i..
12/12 ABBVIE : Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetocl..
More news
News from SeekingAlpha
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/14 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 ARGENX : This ASH Winner Has Further Upside Ahead
12/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 13, 2017
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,67%
P/E ratio 2017 21,01
P/E ratio 2018 16,57
EV / Sales 2017 6,51x
EV / Sales 2018 5,76x
Capitalization 155 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 100 $
Spread / Average Target 3,0%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.78%155 345
MERCK KGAA-9.18%13 747
KYOWA HAKKO KIRIN CO LTD33.44%11 050
JAZZ PHARMACEUTICALS PLC24.28%8 125
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD38.39%5 638
CONVATEC GROUP-13.13%5 395